Merck has agreed to acquire clinical-stage biotech company Prometheus Biosciences for $200 per share in cash, with the deal expected to close late in Q2 or early in Q3. The acquisition will advance ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback